Epstein associate raises $100M for biotech comeback
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Readout LOUD discussed a biotech comeback by a Jeffrey Epstein associate, noting a $100 million fundraising round backed by a prominent biotech VC.
- Vinay Prasad was queried about a possible return to the FDA for a three‑peat of leadership roles.
- Allison DeAngelis co‑hosts the podcast, covering hot startup activity and financing, and can be reached on Signal at AllisonDeAngelis.01.
- Elaine Y. Chen co‑hosts, focusing on obesity treatments, drug payment models, and psychedelics, and is reachable on Signal at elaineywchen.70.
- Adam Feuerstein co‑hosts, writes senior biotech columns, authored Adam’s Biotech Scorecard, and is reachable on Signal at stataf.54.
Why it matters: The $100 million infusion shows that venture capital still backs biotech ventures even when linked to a controversial figure, giving the associate's company a financial runway while signaling investor confidence. Vinay Prasad’s possible FDA comeback could steer regulatory decisions, affecting drug approval pathways and industry stakeholders.
Ask SkimNews
